Member Info for Fevertreeman

A welcome development but with Nero’s hyping ability everything should be put in context! SP reaction takes the share price merely back to where it was in September , so hardly rocket-fuelled, and still half of what it was 12 months ago before the realisation that Newland wasn’t getting commercial contracts across the line etc….

Adams continues to string folks along I see helped by Winnifrith that doyenne of penny stock tips. The chances of this going ahead without Adams again stuffing s/holders Q1 24 have thought is close to zero given his abysmal track record. But happy to be stand corrected

You are absolutely correct BUT once again we have Newland/Griffiths on the one hand hyping the deal, and on the other hand not explaining what the timescale is for the Phase II nor when the $250,000 revenue can be recognised. They continue to behave as if all their investors are idiots, by seemingly deliberately refusing to link deals like this to their revenue outlook! Just so typical of the two of them (no wonder Jefferies got fed up)!

Just go back to the Nov 9 Trading Update. and remember this is a December YE so should be reasonably easy to fo Newland stated that:

"New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year. "

Question 1: Is the Eisai contract a new sale secured in 2023 whose revenue will fall into 2024 FY? Seems that it is so why not bloody confirm this and confirm that the revenue will be recogbnised this year....

If you recall Newland banged on about about

I mean seriously $250k pilot study - is this the deal that AN was desperately touting to Yankee investors! No wonder sp has not responded....

Fingers crossed....expect no follow through from director purchases

Sensible review of CPI. I purchased a slug c18p and have been adding slowly as I felt pretty much all the remedial work had been done and the new CEO is coming on-board with most of the repair work completed. However, whilst the positives outweigh the negatives, a degree of caution is required here - new CEO strategy; weak economic background; over optimism on pace of interest rate reductions; Politics...Labour's view on outsourcing etc....

So is the significant large pharma contract Nero was punting ? If so it’s another case of ludicrous hype from Newland. Yes Eisai is a recognised major pharma name, and yes it is strong validation of parsortix, but and it’s a big but, this hardly validates the commercial case does it? The value of the contract if this is the big one is miniscule: $250,000 is barely going to move the dial for a company burning thro £20m a year. And by revealing the value finally, it gives context to just how tiny the value of previous deals AGL announced but didn’t put a £ next to. It is a good start to the year but Newland is going to have to produce plenty of these types of deals to get the share price back to the mid 30s where it was 12 months ago!

It would be great if NEWLAND’s New Year’s resolution was to keep his mouth shut and stop single handedly destroying share price with ludicrous front-running predictions on toe-ups and results that then don’t materialise!

Bonkers not boners*

Nov 9th Trading Update . Begs the question, why make yourself a hostage to fortune by making this comment? Boners, no one forced them to include such an explicit expectation in the update. So unless s/thing gets done over Xmas, another missed milestone from Newland.

"The extension of our molecular capability across multiple molecular platforms will also support product sales to the customers of the installed base of these molecular platforms as it will drive the generation of a stream of clinical evidence of the value of such analysis, THE FIRST OF WHICH WE EXPECT TO PUBLISH BEFORE THE YEAR END"

Am trying to encourage other shareholders who cant be happy with the way Newland has managed this to voice their grievances. Are you invested, if so then join the chorus?

SO pleased that my moniker for Newland has gained other advocates....his ability to 'fiddle while the company's shareholders burn remains unsurpassed. I am not surprised that Jeffereies walked away after his puffery at the OTC US investors proved the final straw. Listen to what he says - incredible that he cannot control his tongue......

What choice did he have, given Bundred and Johnson took a sledge hammer to the share price. Extraordinarily neither has seen fit to apologise, and Bundred should just leave before he does any more damage as his credibility is shot to pieces and he is a laughing stock

All of the shareholders that Newland has so comprehensively shafted would love to believe you're correct, but as per 2H 2022, throughout FY 2023 Nero has continued his one-man wrecking ball crusade, and the year isn't yet over, so still more room for disappointment (check out his comments to US OTC investors the other week)!. If only one could believe 2024 will be different!

The response from the company to the question of board shareholdings sums up everything that is wrong about Angle -minimal alignment between board and shareholders. Hiding behind the fiction about independence is just typical of a board who've been asleep at the wheel for far too long, typified by the 'pass the parcel' change of chair when Garth Selvey slank off after 16 years (yes seriously you read that correct, made chair in 2007) and was replaced, not by an outsider but another insider, Dr Jan Groen. There are plenty of small cap listed companies on AIM where NEDs own shares in the company whose board they sit on, as it shows they are aligned with the shareholders. Not here of course.

His arrogance and constant public hyping is really starting to hack folk off. The most recent egregious examples being creating hostages to fortune with his comments about imminent deals etc on the US OTC webinar. That may well have been the final straw for Jefferies, who have had enough of his epic ability to shoot his mouth off in public.

Bundred and Johnson remain in place which absolutely does not give me any comfort given the recent disasters....Bundred simply has to go: the longer the two of them remain joined at the hip, the more likely it is that investors will give this a wide berth beyond those of us stuck at much higher levels

You said it! And one non executive director refused to take any!

Fair comment :)

You jest.....30 years of advising listed small. mid, and large caps means I have a good idea, thanks.